Atezolizumab/Hyaluronidase

阿替利珠单抗/透明质酸酶

Report date: 2024/10/12 10:48:22

Base Information

Drug NameAtezolizumab/Hyaluronidase
Drug Alias NameAtezolizumab/Hyaluronidase-TQJSTECENTRIQ HYBREZA
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Enzyme > Recombinant enzymeBiologics > Protein drugs > Recombinant protein > Recombinant enzyme
Mechanisms of ActionProgrammed death-ligand 1 blockersCytotoxic T lymphocytes stimulants
TargetsProgrammed death-ligand 1
Therapy Area/IndicationsSmall Cell Lung CarcinomaCarcinoma, Non-Small-Cell LungCarcinoma, Hepatocellular +[5] 
Global Approved IndicationsSmall Cell Lung CarcinomaCarcinoma, Non-Small-Cell LungCarcinoma, Hepatocellular +[5] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2024/09/12
Country/TerritoryUnited States
CombinationsYes Atezolizumab
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesGenentech Inc
China Registration ClassN/A

Develop Information

Active CompaniesGenentech Inc
Inactive CompaniesN/A
Active IndicationsSmall Cell Lung CarcinomaCarcinoma, Non-Small-Cell LungCarcinoma, Hepatocellular +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A